# Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)

> **NCT00072046** · PHASE3 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 732 (actual)

## Conditions studied

- Kidney Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **BIOLOGICAL:** recombinant interferon alfa

## Key facts

- **NCT ID:** NCT00072046
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2004-01
- **Final completion:** 2012-11
- **Target enrollment:** 732 (ACTUAL)
- **Last updated:** 2016-07-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00072046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00072046, "Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00072046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*